期刊
DIABETOLOGIA
卷 60, 期 2, 页码 287-295出版社
SPRINGER
DOI: 10.1007/s00125-016-4150-x
关键词
Autoantibody-positive; Autoimmunity; BABYDIAB/BABYDIET; LC-MS/MS; Progression time; Risk score; Selected reactionmonitoring; Targeted proteomic; Type 1 diabetes
资金
- JDRF [17-2012-617]
- iMED programme of the Helmholtz Association
- EU [305280]
- German Federal Ministry of Education and Research
Aims/hypothesis We sought to identify minimal sets of serum peptide signatures as markers for islet autoimmunity and predictors of progression rates to clinical type 1 diabetes in a case-control study. Methods A double cross-validation approach was applied to first prioritise peptides from a shotgun proteomic approach in 45 islet autoantibody-positive and -negative children from the BABYDIAB/BABYDIET birth cohorts. Targeted proteomics for 82 discriminating peptides were then applied to samples from another 140 children from these cohorts. Results A total of 41 peptides (26 proteins) enriched for the functional category lipid metabolism were significantly different between islet autoantibody-positive and autoantibody-negative children. Two peptides (from apolipoprotein M and apolipoprotein C-IV) were sufficient to discriminate autoantibody-positive from autoantibody-negative children. Hepatocyte growth factor activator, complement factor H, ceruloplasmin and age predicted progression time to type 1 diabetes with a significant improvement compared with age alone. Conclusion/interpretation Distinct peptide signatures indicate islet autoimmunity prior to the clinical manifestation of type 1 diabetes and enable refined staging of the presymptomatic disease period.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据